prikaz prve stranice dokumenta Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia
  Preuzmi
PDF 443.21 KB
Znanstveni rad - Izvorni znanstveni rad
Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia
Frontiers in Pharmacology, 9 (2018), 705; https://doi.org/10.3389/fphar.2018.00705
Šagud, Marina; Tudor, Lucija; Uzun, Suzana; Perković, Matea Nikolas; Živković, Maja; Konjevod, Marcela; Kozumplik, Oliver; Vuksan Ćusa, Bjanka; Švob Štrac, Dubravka; Radoš, Iva; Mimica, Ninoslav; Mihaljević Peleš, Alma; Nedić Erjavec, Gordana; Pivac, Nela

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Šagud, M., Tudor, L., Uzun, S., Perković, M. N., Živković, M., Konjevod, M. ... Pivac, N. (2018). Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia. Frontiers in Pharmacology, 9. (705). doi: 10.3389/fphar.2018.00705

Šagud, Marina, et al. "Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia." Frontiers in Pharmacology, vol. 9, br. 705, 2018. https://doi.org/10.3389/fphar.2018.00705

Šagud, Marina, Lucija Tudor, Suzana Uzun, Matea Nikolas Perković, Maja Živković, Marcela Konjevod, Oliver Kozumplik, et al. "Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia." Frontiers in Pharmacology 9, br. 705 (2018). https://doi.org/10.3389/fphar.2018.00705

Šagud, M., et al. (2018) 'Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia', Frontiers in Pharmacology, 9(705). doi: 10.3389/fphar.2018.00705

Šagud M, Tudor L, Uzun S, Perković MN, Živković M, Konjevod M, i sur.. Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia. Frontiers in Pharmacology [Internet]. 03.07.2018. [pristupljeno 07.11.2024.];9(705). doi: 10.3389/fphar.2018.00705

M. Šagud, et al., "Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia", Frontiers in Pharmacology, vol. 9, br. 705, Srpanj 2018. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:769077. [Citirano: 07.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:769077
Podaci o radu
Naslov (engleski)Haplotypic and genotypic Association of catechol-O-methyltransferase rs4680 and rs4818 polymorphisms and treatment resistance in schizophrenia
AutorMarina Šagud
AutorLucija Tudor
AutorSuzana Uzun
AutorMatea Nikolas Perković
AutorMaja Živković
AutorMarcela Konjevod
AutorOliver Kozumplik
AutorBjanka Vuksan Ćusa
AutorDubravka Švob Štrac
AutorIva Radoš
AutorNinoslav Mimica
AutorAlma Mihaljević Peleš
AutorGordana Nedić Erjavec
AutorNela Pivac
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Treatment-resistant schizophrenia (TRS) continues to be a challenge. It was related to different factors, including alterations in the activity of brain dopaminergic system, which could be influenced by the dopamine-degrading enzyme, catechol-O-methyltransferase (COMT). Variants of the COMT gene have been extensively studied as risk factors for schizophrenia; however, their association with TRS has been poorly investigated. The aim of the present study was to determine the haplotypic and genotypic association of COMT rs4680 and rs4818 polymorphisms with the presence of TRS. Overall, 931 Caucasian patients diagnosed with schizophrenia (386 females and 545 males) were included, while 270 participants met the criteria for TRS. In males, no significant haplotypic and genotypic associations between COMT rs4680 and rs4818 polymorphisms and TRS were detected. However, genotypic analyses demonstrated higher frequency of COMT rs4680 AA genotype carriers compared to G-allele carriers (p = 0.033) and higher frequency of COMT rs4818 CC genotype carriers than G-allele carriers (p = 0.014) in females with TRS. Haplotype analyses confirmed that the presence of the G allele in females was associated with lower risk of TRS. In women with TRS, the high activity G-G/G-G haplotype was rare, while carriers of other haplotypes were overrepresented (p = 0.009). Such associations of COMT rs4680 and rs4818 high activity (G variants), as well as G-G/G-G haplotype, with the lower risk of TRS in females, but not in males, suggest significant, but sex-specific influence of COMT variants on the development of treatment-resistance in patients with schizophrenia. However, due to relatively low number of females, those findings require replication in a larger sample.
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Pharmacology
Brojčani podacivol. 9, br. 705
p-ISSN1663-9812
DOIhttps://doi.org/10.3389/fphar.2018.00705
URN:NBNurn:nbn:hr:105:769077
Datum objave publikacije2018-07-03
URL dokumentahttps://doi.org/10.3389/fphar.2018.00705
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 10:06:53